Healthy Male Volunteers Over 65NCT07038655
Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique
A study testing Randomised 20g Protein Supplement in people with Healthy Male Volunteers Over 65, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
By 2020, over 20% of the UK population will be over 65 years of age, dramatically increasing pressure on health and social care. Muscle mass is a strong predictor of healthy ageing and longevity. However, ageing is associated with a progressive loss of muscle, so-called sarcopenia, and this begins in mid-life. Read more about this study
- Who is it for?
- Ages 65 to 75 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Male Volunteers Over 65
- What is being tested?
- Randomised 20g Protein Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 25 Apr 2022to 24 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 75 years
- Men only
- Healthy volunteers accepted
- Older adult
Who may be able to join
- -
Who cannot join
- A BMI <18 or >32 kg·m-2
- Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- Respiratory disease including pulmonary hypertension or COPD
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. PKU, galactosaemia)
- Active inflammatory bowel disease
Show all 13Show fewer
- Acute infection
- Acute or chronic renal disease
- Malignancy (or history of malignancy with 5 y)
- Recent steroid treatment (within 6 mo), or hormone replacement therapy
- Coagulopathy
- Musculoskeletal or neurological disorders
- Known allergies to any of the product ingredients
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Royal Derby Hospital Medical School
Derby, Derbyshire, DE22 3NE
About this study
By 2020, over 20% of the UK population will be over 65 years of age, dramatically increasing pressure on health and social care. Muscle mass is a strong predictor of healthy ageing and longevity. However, ageing is associated with a progressive loss of muscle, so-called sarcopenia, and this begins in mid-life. Because of the associated loss of muscle strength and stamina, sarcopenia is a major cause of disability, frailty and loss of independence, and is associated with an increased risk of falling and fractures in older people. Strategies to prevent or reduce sarcopenia are receiving increasing attention due to the growing numbers of elderly members of society, but the links between cause and effect are not easy to discern. The investigator's previous work has shown that there are deficits in mechanisms of muscle protein synthesis (MPS) in older people, but why these deficits exist and how they might be countered is still unknown. One of the major problems with ageing is that stimuli which would normally, in younger people, help maintain muscle by turning on MPS (to build muscle) are less effective in older people. The investigator's research has shown that in muscle, the major stimulant of adult human MPS is the availability of the so-called essential amino acids (AA) (which we have to obtain from our diet). After normal feeding, AA and insulin availability both rise, causing net gain of muscle protein. Although these processes do occur in the muscle of older people, they do not occur to the same extent as in the young. Similar results have also been obtained by others, and this is called "anabolic resistance". To exemplify, recent data the investigators have produced showed that: i) increasing the amount of protein provided has a smaller anabolic effect on MPS in older people, and ii) the anabolic response to acute resistance exercise is also less in older people.
Understanding the basic mechanisms underlying age-associated muscle loss would help to define possible counter-measures, such as optimal nutritional strategies. The investigators believe that one contributing factor to the observed "anabolic resistance" of age could be changes in digestive capacity with advancing age, limiting the availability and uptake of ingested dietary proteins. Much of the work to-date relating to protein nutrition and ageing muscle has focussed on whey (WP) and casein proteins (CP), with a wealth of knowledge about the bio-availability of these protein sources across the lifespan. Much less is known about the 'digestibility' of other protein sources (e.g. soy, collagen), with particularly limited knowledge about the interaction between these other protein sources and the second major anabolic stimulus (other than AA feeding), that of resistance exercise. Discovery of a protein blend (PB) with equal capacity for increasing MPS (vs. WP and/or CP)), both at rest and in combination with resistance exercise, plus further knowledge about the bio-availability of different protein sources, will offer new insight for the development of optimal feeding strategies for older adults to counter sarcopenia and the associated health detriments.
In light of difficulties in ileal sampling in studies assessing protein digestibility and absorption in humans, a dual stable isotope approach has been proposed as the ideal solution to determine protein digestibility and absorption; this has been successfully applied and validated in adult humans. This non-invasive approach involves the ingestion of an intrinsically stable isotopically labelled protein, as a single bolus (like a meal) or as intermittent small boluses. Simultaneously, known amounts of differently stable isotopically labelled free amino acids are given with each bolus. The labelled free amino acids are assumed to represent fully digested protein AA and their availability is set at 100, the subsequent appearance of labelled amino acid from the intrinsically labelled protein, of known AA composition and labelling, provides a measure of the digestibility of the protein, as a fraction/percentage of the free AA. In the absence of a suitable intrinsically labelled protein e.g. whey or similar, universally labelled Spirulina (U-13C AA, Cambridge Isotope Laboratories, MA, USA), can be added as a 'labelled or test' protein to any protein meal/source, and report on the digestion of the protein under investigation. This approach has also been successfully applied in patients with cystic fibrosis revealing their reduced ability to digest protein and the positive impact of providing pancreatic enzymes to increase digestion and South Indian children with stunted growth to investigate the digestibility of alternative protein sources i.e. legumes. The investigators aim to use this approach to determine the digestibility of the protein sources in these studies, to assess the bioavailability of amino acids and, in addition, their subsequent utilisation for muscle protein synthesis.
- Conditions
- Healthy Male Volunteers Over 65
- Being tested
- Randomised 20g Protein Supplement
- Keywords
- Digestibility, Muscle Mass, Sarcopenia, Nutrition, Protein
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Randomised 20g Protein SupplementDietary supplement
Participants receive a 20g protein feed of their randomised blend over the course of five hours split into aliquots every twenty minutes. The drink also contains a top up of 13C2 leucine stable isotope tracer, as well as uniformly labelled 13C spirulina and 2H labelled free amino acids for quantification of digestibility.
| Study group | Role | What they receive |
|---|---|---|
| Drink A | Experimental | 51: 49, casein: soy blend Receives: Dietary Supplement: Randomised 20g Protein Supplement |
| Drink B | Experimental | 35: 25: 20: 20, whey: casein: soy: pea blend Receives: Dietary Supplement: Randomised 20g Protein Supplement |
| Drink C | Experimental | 35: 25: 20: 20, whey: casein: soy: pea blend Receives: Dietary Supplement: Randomised 20g Protein Supplement |
| Drink D | Experimental | 80: 20, casein: whey blend Receives: Dietary Supplement: Randomised 20g Protein Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle Protein Synthesis
We measure muscle protein synthesis based on the incorporation of 13C2 leucine into the muscle, which is provided through a constant intravenous infusion throughout the study.
Measured: Following enrolment, the study period lasts for a single, approximately ten hour day.
Protein Digestibility
We are measuring the protein digestibility using a dual stable isotope tracer technique. This involves the inclusion of a 13C labelled spirulina protein in the drink alongside a 2H labelled free amino acid mixture. The free amino acid mixture acts as a reference, representing 100% (or complete) digestibility. The spirulina protein acts as a labelled reporter protein, and based on the dilution of the 13C label from this spirulina, we can quantify the digestibility of the experimental protein blends.
Measured: Following enrolment, the participants complete a single, approximately ten hour study visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2025
- Study start25 Apr 2022
- Primary completion24 Oct 2023
- Study completion24 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Healthy Male Volunteers Over 65Studies of the same condition, open and under way.
- More trials run by University of NottinghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- Fresenius Kabi
- Responsible party
- Principal investigator, Philip Atherton, University of Nottingham
- Investigators
- Philip J Atherton, Principal investigator, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07038655
- Sponsor's protocol ID
- DBU2- FMHS 116-1120
- Status last verified
- Jun 2025
- First submitted
- 30 May 2025
- Last updated
- 26 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cox J, Phillips BE, Bunce J, Smart T, Wall J, Crossland H, Wilkinson DJ, Smith K, Atherton PJ. Investigating the Digestibility, Bioavailability and Utilization of Protein Blends in Older Adults Using a Dual Stable Isotope Tracer Technique. Nutrients. 2025 Oct 23;17(21):3328. doi: 10.3390/nu17213328.
PubMed 41228401
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique
- ClinicalTrials.gov ID
- NCT07038655
- Acronym / sponsor ID
- DBU2- FMHS 116-1120
- Conditions
- Healthy Male Volunteers Over 65
- Keywords
- Digestibility, Muscle Mass, Sarcopenia, Nutrition, Protein
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- Fresenius Kabi
- Study start
- 25 Apr 2022 (actual)
- Primary completion
- 24 Oct 2023 (actual)
- Study completion
- 24 Oct 2023 (actual)
- First posted
- 26 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
By 2020, over 20% of the UK population will be over 65 years of age, dramatically increasing pressure on health and social care. Muscle mass is a strong predictor of healthy ageing and longevity. However, ageing is associated with a progressive loss of muscle, so-called sarcopenia, and this begins in mid-life. Because of the associated loss of muscle strength and stamina, sarcopenia is a major cause of disability, frailty and loss of independence, and is associated with an increased risk of falling and fractures in older people. Strategies to prevent or reduce sarcopenia are receiving increasing attention due to the growing numbers of elderly members of society, but the links between cause and effect are not easy to discern. The investigator's previous work has shown that there are deficits in mechanisms of muscle protein synthesis (MPS) in older people, but why these deficits exist and how they might be countered is still unknown. One of the major problems with ageing is that stimuli which would normally, in younger people, help maintain muscle by turning on MPS (to build muscle) are less effective in older people. The investigator's research has shown that in muscle, the major stimulant of adult human MPS is the availability of the so-called essential amino acids (AA) (which we have to obtain from our diet). After normal feeding, AA and insulin availability both rise, causing net gain of muscle protein. Although these processes do occur in the muscle of older people, they do not occur to the same extent as in the young. Similar results have also been obtained by others, and this is called "anabolic resistance". To exemplify, recent data the investigators have produced showed that: i) increasing the amount of protein provided has a smaller anabolic effect on MPS in older people, and ii) the anabolic response to acute resistance exercise is also less in older people.
Understanding the basic mechanisms underlying age-associated muscle loss would help to define possible counter-measures, such as optimal nutritional strategies. The investigators believe that one contributing factor to the observed "anabolic resistance" of age could be changes in digestive capacity with advancing age, limiting the availability and uptake of ingested dietary proteins. Much of the work to-date relating to protein nutrition and ageing muscle has focussed on whey (WP) and casein proteins (CP), with a wealth of knowledge about the bio-availability of these protein sources across the lifespan. Much less is known about the 'digestibility' of other protein sources (e.g. soy, collagen), with particularly limited knowledge about the interaction between these other protein sources and the second major anabolic stimulus (other than AA feeding), that of resistance exercise. Discovery of a protein blend (PB) with equal capacity for increasing MPS (vs. WP and/or CP)), both at rest and in combination with resistance exercise, plus further knowledge about the bio-availability of different protein sources, will offer new insight for the development of optimal feeding strategies for older adults to counter sarcopenia and the associated health detriments.
In light of difficulties in ileal sampling in studies assessing protein digestibility and absorption in humans, a dual stable isotope approach has been proposed as the ideal solution to determine protein digestibility and absorption; this has been successfully applied and validated in adult humans. This non-invasive approach involves the ingestion of an intrinsically stable isotopically labelled protein, as a single bolus (like a meal) or as intermittent small boluses. Simultaneously, known amounts of differently stable isotopically labelled free amino acids are given with each bolus. The labelled free amino acids are assumed to represent fully digested protein AA and their availability is set at 100, the subsequent appearance of labelled amino acid from the intrinsically labelled protein, of known AA composition and labelling, provides a measure of the digestibility of the protein, as a fraction/percentage of the free AA. In the absence of a suitable intrinsically labelled protein e.g. whey or similar, universally labelled Spirulina (U-13C AA, Cambridge Isotope Laboratories, MA, USA), can be added as a 'labelled or test' protein to any protein meal/source, and report on the digestion of the protein under investigation. This approach has also been successfully applied in patients with cystic fibrosis revealing their reduced ability to digest protein and the positive impact of providing pancreatic enzymes to increase digestion and South Indian children with stunted growth to investigate the digestibility of alternative protein sources i.e. legumes. The investigators aim to use this approach to determine the digestibility of the protein sources in these studies, to assess the bioavailability of amino acids and, in addition, their subsequent utilisation for muscle protein synthesis.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Drink A | Experimental | Dietary Supplement: Randomised 20g Protein Supplement51: 49, casein: soy blend |
| Drink B | Experimental | Dietary Supplement: Randomised 20g Protein Supplement35: 25: 20: 20, whey: casein: soy: pea blend |
| Drink C | Experimental | Dietary Supplement: Randomised 20g Protein Supplement35: 25: 20: 20, whey: casein: soy: pea blend |
| Drink D | Experimental | Dietary Supplement: Randomised 20g Protein Supplement80: 20, casein: whey blend |
Who may qualify
- Ages
- 65 to 75 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (13 listed)
- A BMI <18 or >32 kg·m-2
- Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- Respiratory disease including pulmonary hypertension or COPD
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. PKU, galactosaemia)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Randomised 20g Protein SupplementParticipants receive a 20g protein feed of their randomised blend over the course of five hours split into aliquots every twenty minutes. The drink also contains a top up of 13C2 leucine stable isotope tracer, as well as uniformly labelled 13C spirulina and 2H labelled free amino acids for quantification of digestibility. | Dietary supplement | Drink A, Drink B, Drink C, Drink D |
Primary outcome
Muscle Protein Synthesis
Time frame: Following enrolment, the study period lasts for a single, approximately ten hour day.
We measure muscle protein synthesis based on the incorporation of 13C2 leucine into the muscle, which is provided through a constant intravenous infusion throughout the study.
Protein Digestibility
Time frame: Following enrolment, the participants complete a single, approximately ten hour study visit.
We are measuring the protein digestibility using a dual stable isotope tracer technique. This involves the inclusion of a 13C labelled spirulina protein in the drink alongside a 2H labelled free amino acid mixture. The free amino acid mixture acts as a reference, representing 100% (or complete) digestibility. The spirulina protein acts as a labelled reporter protein, and based on the dilution of the 13C label from this spirulina, we can quantify the digestibility of the experimental protein blends.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2025.
- Derived from this study: PubMed 41228401Cox J, Phillips BE, Bunce J, Smart T, Wall J, Crossland H, Wilkinson DJ, Smith K, Atherton PJ. Investigating the Digestibility, Bioavailability and Utilization of Protein Blends in Older Adults Using a Dual Stable Isotope Tracer Technique. Nutrients. 2025 Oct 23;17(21):3328. doi: 10.3390/nu17213328.
- Individual participant dataSharing planned: No
Related trials for Healthy Male Volunteers Over 65
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip J Atherton principal investigator
University of Nottingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Randomised 20g Protein Supplement in people with Healthy Male Volunteers Over 65, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscle Protein Synthesis (time frame: Following enrolment, the study period lasts for a single, approximately ten hour day.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07038655, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2025.